Background--Pigment epithelium-derived factor (PEDF), which belongs to the noninhibitory serpin family, has shown the ability to stimulate several physiological processes, such as antiangiogenesis, anti-inflammation, and antioxidation. In the present study, the effects of PEDF on contractility and calcium handling of rat ventricular myocytes were investigated.
M
yocardial infarction (MI) is one of the leading causes of morbidity and mortality with death related to pump failure as well as to arrhythmias. 1 In recent years, mortality with acute myocardial infarction (AMI) has decreased as efficient thrombolytic therapy and acute revascularization (angioplasty, stenting) have become available. However, preventing or reversing ventricular remodeling and the evolution toward end-stage heart failure presents a new challenge. 2 Various strategies are being explored, and the reduced contraction of the ischemic myocardium is considered to be 1 of the targets. Maintaining myocyte contractility post-MI, by increasing Ca 2+ influx, exacerbates cardiac injury and pump dysfunction post-MI by reducing myocyte number. 3 Therefore, the depressed myocyte contractility and Ca 2+ influx may improve cardiac pump function and present a therapeutic strategy for AMI. Calcium is the key factor of contractility. Development of contractility force depends on free intracellular Ca 2+ concen- 2+ handling and thus plays a critical role in initiating cardiac contraction and relaxation, and it could be modulated through its accessory phosphoprotein, phospholamban (PLN). 5 Activation of protein kinase C alpha (PKCa) has been associated with protection from heart failure through augmented cardiac Ca 2+ handling. 6 The PKC family functions downstream of many signal transduction pathways, 7 and PKCa is the predominant conventional PKC isoform expressed in the mouse, rat, and human heart. 8 PKCa could be 1 of the pathways to decrease cardiac contractility through reducing sarcoplasmic reticulum (SR) Ca 2+ load and Ca
2+
release during systole through regulation of SERCA2a. Pigment epithelium-derived factor (PEDF) is a 50-kDa secreted multifunctional protein of the SERPIN superfamily that has been implicated in many cardiovascular diseases. [9] [10] [11] PEDF is expressed in multiple tissues and has many biological activities, such as antiangiogenesis, antioxidation, and cytoprotection. 12, 13 PEDF could inhibit tissue remodeling and improve cardiac function through antioxidant and antiinflammatory actions in AMI rats. 14 Our previous studies also found that PEDF could prevent hypoxia-induced apoptosis and necroptosis in vitro and improve cardiac function post-AMI in vivo. 15, 16 However, whether PEDF affects cardiac contractility and myocyte calcium handling post-AMI is still unclear. PEDF mainly deposits in the cell membrane and interacts with its receptors. It is known that the 80-kDa phospholipaseA2/nutrin/patarin-like phospholipase domain-containing 2 PEDF receptor (PEDF-R) and 67-kDa laminin receptor (LR) are two crucial receptors among PEDF binding sites. 17, 18 PEDF-R is the key enzyme of triglyceride (TG) catabolism and functions as a monoacyl hydrolase that catalyzes the initial, rate-limiting step of the TG lipolysis cascade. 19 PEDF-R specifically initiates the first step in lipolysis, generating diacylglycerols (DAGs) and FAs. DAG accumulation can activate PKC by converting itself to phosphatidic acid through diacylglycerol kinase. 20 Our previous studies have demonstrated that PEDF could promote TG degradation in cardiomyocytes post-AMI through PEDF-R. 21 However, whether PEDF facilitates DAG accumulation and regulates PKCa signaling through PEDF-R post-AMI is still unknown.
In the present study, we hypothesized that PEDF upregulates DAG-PKCa signaling and decreases intracellular calcium levels by PEDF-R, thus depressing hypoxic myocyte contractility and improving ischemic cardiac functional reserve. This may provide a novel therapeutic target for AMI.
Methods

Recombinant Lentivirus Constructs and Viral Production
Recombinant PEDF-lentivirus (PEDF-LV) was prepared as described previously. 16 PEDF overexpression plasmids and the RNAi vector, PEDF-R-RNAi-LV, of the PEDF-R gene producing PEDF-R shRNA were successfully constructed and were then packaged in 293T cells. The RNAi vector, LR-RNAi-LV, of the LR gene was also constructed. The concentrated titer of virus suspension was 2910 12 TU/L.
Preparations of PEDF Protein
Recombinant rat PEDF (GenBankTM accession number: NM_177927) was synthesized by Cusabio Biotech, Co., Ltd. (Wuhan, China). In brief, 293T cells were transfected with the recombinant vector pGEX 6P-1 glutathione S-transferase (GST)-tagged PEDF. GST-tagged PEDF proteins were purified by high-pressure liquid chromatography purification (>90% purity) and amino-terminal sequence determination. The resulting proteins were soluble in aqueous solutions.
Animal Model and Intramyocardial Gene Delivery
Myocardial ischemia was induced by ligation of the left anterior descending coronary artery (LAD) in anesthetized rats, as described previously. 22 
Quantification of Myocardial Infarct Size
Two weeks after LAD artery ligation, 2% Evans Blue dye (30 mg/kg; Sigma-Aldrich) was injected intravenously for 10 minutes and selected rats were euthanized. Then, hearts were removed for myocardial infarct size analyses by the method of 2,3,5-triphenyltetrazolium (TTC) staining. 16 The left ventricle was isolated and cut into 4-mm slices perpendicular to the axis of the LAD. Then, slices were immediately immersed in 1% TTC (Sigma-Aldrich) in phosphate buffer (pH 7.4) at 37°C for 10 minutes to discriminate infarcted tissue from viable myocardium. All slices were scanned from both sides by a color CCD camera (FV-10; Fujifilm, Tokyo, Japan), and in each slide, infarct area was compared with the total area by using digital planimetry software (Image-Pro Plus 6.0; Media Cybernetics Inc., Bethesda, MD). After correction with the weight of the slices, infarct size was calculated as a percentage of the left ventricle.
Transmission Electron Microscopy Imaging and Analyses
For transmission electron microscopy observation, small samples of heart tissue were fixed in 2.5% glutaraldehyde overnight and then incubated in 1% osmium tetroxide for 2 hours with lightproof. After washing in distilled water, specimens were incubated in 2% uranyl acetate for 2 hours at room temperature and then dehydrated in graded ethanol concentrations. Finally, samples were embedded in molds with fresh resin. Ultrathin sections were cut with an EM UC7 (Leica Microsystems GmbH, Wetzlar, Germany), stained with lead citrate and examined with a Tecnai G2 T12 (FEI, Hillsboro, OR). In these images, we measured mean sarcomere length (SL) to test myocardial contracture by using digital planimetry software (Image-Pro Plus 6.0; Media Cybernetics).
Images with large SL heterogeneities were excluded from analysis. 25 
Rat Primary Cardiomyocytes Cultures and Hypoxia
Cardiomyocytes were isolated from 1-day-old newborn Sprague-Dawley rats. 26 In brief, neonatal rats were anesthetized with sodium pentobarbital and killed by means of decapitation, and hearts were rapidly removed and placed into dishes on ice. After atria and vessels were discarded, hearts were minced into 1-mm 3 
Measurement of Single-Cell Contractility
Myocytes were cultured for 24 hours in standard growth medium in Plexiglas superfusion chambers, in which the bottom was formed by a collagen-coated glass coverslip. The chamber was then placed on the stage of an inverted microscope (Nikon Diaphot; Nikon Corporation, Tokyo, Japan), and cells were cultured in D-Hank's liquid with glucose deprivation in a tri-gas incubator saturated with 5% CO 2 /1% O 2 at 37°C for 24 hours. Cell shortening was measured using a video edge detection system (Crescent Electronics, Sandy, UT). The signal was acquired using a Data Q DI-200 board interfaced to a personal computer and stored using WinDaq software (DATAQ Instruments, Inc., Akron, OH). The cell image was also recorded on videotape for additional off-line analysis. Amplitude of contraction under hypoxia condition was expressed relative to control values. Contractile amplitude under normoxia condition was set to 100%.
Measurement of Intracellular Ca 2+ Concentration
Myocytes were loaded with the fluorescent indicator, Fura-2-acetoxymethyl ester (Fura 2-AM; Molecular Probes, Eugene, OR) as described previously. 27 In brief, 4 lL of a 1-mmol/L buffer. Protein was separated by 10% SDS-PAGE and transferred to nitrocellulose membrane (Millipore, Billerica, MA 
Statistical Analysis
Results are expressed as the meansAESE. Statistical analysis of the results was carried out using the Student t test or repeated-measures 1-way ANOVA followed by Duncan's new multiple range method or least significant difference test. P<0.05 was considered significant.
Results
PEDF Increases Cardiac Functional Reserve and Reduces Ischemic Contracture in AMI Rat Hearts
Of the 14 rats entered into the present experiment, they were divided into PEDF or vehicle treatment groups. We first examined expression of PEDF and PEDF-R after 2 weeks of MI ( Figure 1A) . Results showed that protein levels of PEDF decreased and protein levels of PEDF-R increased 2 weeks post-AMI ( Figure 1B and 1C) . Then, the PEDF-LV was successfully transfected into myocardium and confirmed by its green fluorescent protein (GFP) fluorescence ( Figure 1D ). ELISA analysis showed that protein levels of PEDF in the PEDFtransfected group significantly increased compared to those of the control group and could reach up to 9.55 nmol/L ( Figure 1E ). Cardiac contractile function was measured at 2 weeks post-MI using transthoracic M-mode echocardiography before and after dobutamine (1 lg/g) injection (Figure 2A and 2B). The delta ejection fraction (DEF) and delta fractional shortening to dobutamine infusions were both significantly higher in hearts transfected with PEDF compared to untreated MI hearts ( Figure 2C and 2D) . Evaluation of cardiac reserve (stress-rest) clearly indicated that PEDF treatment had increased delta CO, compared to the MI group, during dobutamine challenge ( Figure 2E ). In addition, PEDF treatment also showed reduced myocardial infarct size compared to the vector control in AMI rats ( Figure 2F and 2G). We next examined myocardial tissues transfected with PEDF or vector at cellular levels. Cross-sections with an ellipticity larger than 0.96 were not used for further analysis. Figure 3A through 3D shows representative images from each group. Interestingly, the bordering areas transfected with PEDF have a longer SL than the areas in the MI group ( Figure 3F ). However, we did not find any significant difference in remote areas between the PEDF and MI groups ( Figure 3E ). Electronic microscope observations reveal that PEDF may protect bordering myocardial tissues from ischemic contracture.
PEDF Promotes a Rapid Depression of Contractility in Hypoxic Neonatal Cardiomyocytes
Cultured rat neonatal cardiomyocytes provide a useful model to understand cardiovascular diseases in vitro on a real-time cell analysis system, so we further verified the protective effects of PEDF on contractility in neonatal cardiomyocytes. The RNAi vector, PEDF-R-RNAi-LV, of the PEDF-R gene producing PEDF-R shRNA and LR were successfully transfected in neonatal cardiomyocytes and were then successfully confirmed by its GFP fluorescence ( Figure 4D ). Immunostaining for a-SA showed the establishment of neonatal cardiomyocytes in vitro (Figure 4A through 4C) . A video edge detection system was used to monitor the effects of PEDF (10 nmol) on hypoxiainduced single-cell contraction changes. Spontaneously beating myocytes added with isoproterenol (1 lm) were exposed to hypoxia for 24 hours with or without PEDF pretreatment. Similarly, PEDF had no significant effect on cell contractility in cultured neonatal cardiomyocytes under normal culture conditions ( Figure 5A and 5C) . Contractility was then measured during the exposure to hypoxia period ( Figure 5B and  5D ). All groups' contractions decreased with the extension of hypoxic time and PEDF pretreatment, showing a more-rapid time-dependent trend. PEDF caused a significant decrease in contraction amplitude of spontaneously beating myocytes after 3 hours of hypoxia that persisted throughout the following 8 hours until it was stable. These results clearly demonstrated that PEDF promotes a rapid and significant decrease of contractility in hypoxic neonatal cardiomyocytes, but has no effects on normoxic cardiomyocytes.
PEDF Decreases Intracellular Calcium Levels in Hypoxic Neonatal Cardiomyocytes
Curves of [Ca 2+ ]i levels were measured in beating cardiomyocytes isolated from neonatal cardiomyocytes, which were driven by isoproterenol stimulation (Figure 6A through 6F). Consistent with depressed cellular contractility, hypoxic neonatal myocytes with PEDF treatment (10 nmol) showed decreased Ca 2+ transient amplitudes compared to the hypoxia group ( Figure 6H ). Similarly, PEDF also had no influence on normoxia cardiomyocytes. We next investigated the SR Ca 2+ load after 12 hours of hypoxia in cultured cardiomyocytes ( Figure 7A ). We confirmed less SR Ca 2+ loads in PEDF-treated cardiomyocytes compared to hypoxia groups ( Figure 7B ). Furthermore, PEDF treatment (10 nmol) cardiomyocytes showed reduced PLN phosphorylation, which would decrease SERCA2 activity and SR Ca 2+ load ( Figure 7C and 7D) . No other changes were observed in levels of PLN and SERCA2 proteins in cultured neonatal cardiomyocytes. Together, these results suggest that PEDF decreases intracellular calcium levels through PLN dephosphorylation in hypoxic neonatal cardiomyocytes.
PEDF Decreases Hypoxic Cardiomyocyte Contractility and Intracellular Calcium Levels Through PEDF-R
To investigate which receptor was involved in PEDF effects on contractility depression and intracellular calcium decrease, the PEDF-R-siRNA (siRNA)-lentivirus (PEDF-R-RNAi-LV) and LR-RNAi-LV were administered. We first confirmed that neither PEDF-R-LV nor LR-LV alone changed the contractions (Figure 4E and 4F) and intracellular calcium ( Figure 6G ) of hypoxic cardiomyocytes. PEDF-treated (10-nmol) cultures plus PEDF-R-LV caused a significant increase in contraction amplitude of spontaneously beating cardiomyocytes compared with PEDF alone under hypoxia condition ( Figure 5B and 5D) . A significant increase in intracellular calcium levels was also observed in PEDF-treated cultures plus PEDF-R-LV compared to the PEDF group ( Figures 6H and 7B ). PEDF treatment myocytes plus PEDF-R-LV also showed increased PLN phosphorylation (Figure 7D) . Nevertheless, there was no significant difference between PEDF-treatment cardiomyocytes and PEDF plus LR-LV under hypoxia condition. These results indicated that the effects of PEDF on contractility and calcium handling of hypoxic cardiomyocytes are mediated through PEDF-R. Results show that PEDF (10 nmol)-pretreated cardiomyocytes showed a more-rapid time-dependent contraction reduction, and the effects could be attenuated by PEDF-R interference. No significant difference was observed between PEDF and PEDF+siLR groups. LV indicates lentivirus; PEDF, pigment epithelium-derived factor; PEDF-R, PEDF receptor.
PEDF Decreases Hypoxic Cardiomyocyte Contractility and Intracellular Calcium Levels Through DAG-PKCa Signaling
The PKCa pathway inhibitor was utilized in these experiments. We first discovered that PEDF (10 nmol) upregulates protein expression of PKCa through PEDF-R signaling ( Figure 8B) . Notably, PEDF did not increase protein levels of PKCa under normal condition. The PKCa inhibitor, staurosporine (STS), plus PEDF was able to attenuate the effects of PLN dephosphorylation in hypoxic cardiomyocytes ( Figure 7C and 7D) . No other changes were observed in levels of PLN and SERCA2 proteins in cultured neonatal myocytes. Next, we tested whether PEDF upregulates the protein, PKCa, in a DAG-dependent manner. ELISA analysis showed that PEDF induced diglyceride increase in hypoxic cardiomyocytes ( Figure 8A ). The increase was also inhibited by PEDF-R-RNAi-LV, and there were no changes under normal condition. These results indicated that PEDF promotes DAG accumulation and upregulates PKCa through PEDF-R. PEDF may decrease hypoxic cardiomyocyte contractility and intracellular calcium levels through DAG-PKCa signaling with PEDF-R involved in the process. 
Discussion
The results of this study indicate, for the first time, that PEDF depresses hypoxic myocyte contractility and improves ischemic cardiac functional reserve through its receptor, PEDF-R, and DAG-PKCa signaling and intracellular calcium participate in the effects of PEDF on hypoxic myocyte contractility and ischemic cardiac functional reserve.
In our experiments, we used video edge detection system to measure single-cell-level contractility in a relatively isolated environment without the influence of autonomic nerve endings, gap junctions, and a neurotransmitter uptake system. We found that PEDF caused a significant reduction in the hypoxic myocyte contraction and calcium amplitudes without altering them under a normal oxygen environment. These findings provide evidence that the negative inotropic effect of PEDF just exists under hypoxic condition. In combination with the electronic microscope observations, PEDF probably decreases the myocardial contraction in bordering infarction areas and has no effects on remote regions. This may also explain the difference of contractile changes in vitro and in vivo. The fascinating difference may be attributed to the cardiomyocyte contraction changes in the bordering zones of MI. The reduced contraction of ischemic myocardial is considered to be an adaptive response with contraction perfusion matching. 28 PEDF may decrease the ischemic cardiomyocyte contractility in bordering areas and thus reduce the energy expenditure to adapt to the anoxic environment. Therefore, this response reduces energy consumption and ischemic myocardial contracture and brings better cardiac functional reserve post-AMI. PEDF was originally identified as a secreted protein found in high levels in circulation. 29 The binding of PEDF to its receptor is presumably the first step in the mediation of its physiological effects. PEDF signaling is triggered by binding of PEDF to its receptors, PEDF-R and LR. In our experiments, we have demonstrated that PEDF promotes a significant decrease in contractility in hypoxic neonatal cardiomyocytes through its receptor, PEDF-R, but has no effect on normoxic cells. This discrepancy above may be attributed to the increased expression of PEDF-R in hypoxic cells. LR was not involved in the process of contraction. Unlike LR involved in the antiangiogenic activity of endothelial cells, 18 PEDF-R may mediate diverse physiological effects in cardiomyocytes. PEDF may perform different biological functions in different tissues through different receptors. Meanwhile, some investigations about the effect of PEDF on cardiomyocytes are still controversial. Our in vitro study showed that PEDF could prevent hypoxia-induced apoptosis and necroptosis in cardiomyocytes, whereas Rychli et al. have shown that circulating PEDF may contribute to progression of heart failure by inducing apoptosis in human cardiac myocytes and fibroblasts. 30 Given that PEDF is constitutively expressed by cardiac myocytes and fibroblasts, the increase of PEDF plasma concentration may be attributed to the release of injured cells. Under anoxic conditions, PEDF expression was reduced both in cardiomyocytes and ischemic myocardium. We therefore used PEDF LVs and exogenous proteins to upregulate local PEDF expression and found that PEDF decreases ischemic myocardial contracture and improves functional reserve in vivo and reduces hypoxic cardiomyocyte contractility in vitro. PEDF is especially needed for its beneficial effects under hypoxic conditions. Our previous in vitro studies have established that 10 nmol/L is the optimal concentration of myocardial protection. So, we used the concentration in our experiments. We also injected LVs into ischemic cardiac tissues to continuously overexpress PEDF and confirmed that the protein levels of PEDF in vivo could sufficiently reach the requirement of the optimal concentration in vitro.
Our present study is the first to report the participation of DAG-PKCa signaling and intracellular calcium in PEDF signaling. We found that PEDF induced DAG accumulation and increased expression of PKCa in hypoxic cardiomyocytes. PKCa has been associated with regulating myocytes calcium handling and contractility. 6 Thus, PEDF may decrease hypoxic cardiomyocyte calcium handling and contractility through DAGPKCa signaling through PEDF-R. DAG accumulation may be associated with PEDF-R property, which catalyzes the initial, rate-limiting step of the TG lipolysis cascade. 19 Specifically, DAG has been shown in a variety of model systems to activate PKC family kinases and mediates diverse physical activities. 31, 32 Our finding of DAG accumulation may broaden the potential clinical value of PEDF for its hydrolysis property. To establish the essential role of PKCa in PEDF signaling, we used PKCa antagonist to inhibit PKCa and confirmed the participation of PKCa in dephosphorylation of PLN. One final issue is how PEDF mechanistically reduces hypoxic cardiomyocyte contractility. Alterations in PLN phosphorylation regulate SERCA2a function in the heart, which controls calcium loading and magnitude of the calcium transient. 5 Here,
we observed a similar reduction in PLN phosphorylation at serine 16 in PEDF-treated cardiomyocytes. Thus, PEDF represents an approach toward achieving hypoxic contractility depression through an SR-dependent mechanism, which could benefit MI. Alternatively, it is also possible that PEDF reduces cardiac contractility through some mechanisms involving the phosphorylation status of select myofilament proteins or other unknown signaling. Regardless of these possibilities, our present data strongly suggest that PEDF decreases intracellular calcium levels through DAG-PKCa signaling through PEDF-R, therefore depressing hypoxic myocyte contractility and improving ischemic cardiac functional reserve.
